Résumé
Study design: Clinical practice guidelines. Objectives: The objective was to update the 2016 version of the Canadian clinical practice guidelines for the management of neuropathic pain in people with spinal cord injury (SCI). Setting: The guidelines are relevant for inpatient, outpatient and community SCI rehabilitation settings in Canada. Methods: The guidelines were updated in accordance with the Appraisal of Guidelines for Research and Evaluation II tool. A Steering Committee and Working Group reviewed the relevant evidence on neuropathic pain management (encompassing screening and diagnosis, treatment and models of care) after SCI. The quality of evidence was scored using Grading of Recommendations Assessment, Development and Evaluation (GRADE). A consensus process was followed to achieve agreement on recommendations and clinical considerations. Results: The working group identified and reviewed 46 additional relevant articles published since the last version of the guidelines. The panel agreed on 3 new screening and diagnosis recommendations and 8 new treatment recommendations. Two key changes to these treatment recommendations included the introduction of general treatment principles and a new treatment recommendation classification system. No new recommendations to model of care were made. Conclusions: The CanPainSCI recommendations for the management of neuropathic pain after SCI should be used to inform practice.
Langue d'origine | English |
---|---|
Journal | Spinal Cord |
DOI | |
Statut de publication | Accepted/In press - 2022 |
Note bibliographique
Funding Information:TJ is employed by the Ontario Neurotrauma Foundation. DEM reports personal fees from Canopy Growth Inc, outside the submitted work. CO’C reports grants from Praxis Spinal Cord Institute, other from Cytokinetics, other from Orion, other from Mallinckrodt, grants from New Brunswick Health Research Foundation, personal fees from Spectrum/Canopy, personal fees from Shoppers Drug Mart, grants and personal fees from IPSEN, personal fees from MT Pharma, personal fees from Tilray, personal fees from Allergan, personal fees from Roche, outside the submitted work. RT reports other funding from Allergan (Predictive Model for Treatment of Spasiticity Post Stroke (Botox), chair positions on data monitoring/advisory boards for studies on statins for osteoporosis after SCI and exercise in SCI, and medicolegal work for assessment of individuals with whiplash and other musculoskeletal injuries after motor vehicle accidents outside the submitted work. All other authors have nothing to disclose.
Funding Information:
Funding for the research and publication of this supplement is provided by the Ontario Neurotrauma Foundation in their mission to advance the care of people with spinal cord injury (Grant 2018-RHI-GUIDE-1049).
Publisher Copyright:
© 2022, The Author(s).
ASJC Scopus Subject Areas
- Rehabilitation
- Neurology
- Clinical Neurology
PubMed: MeSH publication types
- Journal Article
- Practice Guideline